Mark Schoenebaum, ISI Group analyst, explains why he thinks Pfizer will modestly beat expectations tomorrow and discusses several new drugs in the company's pipeline.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT